University of Queensland researchers are leading the charge in adapting drug dosing to a society that is changing shape.
As the level of obesity in the Western World continues to rise dramatically, UQ School of Pharmacy's Dr Bruce Green says researchers face the ongoing challenge of determining just how dosages should be adjusted for different body sizes and compositions.
“In a pharmacological sense, obesity presents a challenging role for clinicians, as the effects of altered body composition on the time course of drug response are poorly understood,” Dr Green said.
“[This] lack of dosing information… [is of additional concern when you] consider that many of these individuals require therapeutic intervention for a variety of disease states.”
It is this shortfall that the School of Pharmacy's Modelling and Simulation Group is looking to redress, as they work to optimise dosages for a variety of drugs in the overweight population.
“The purpose of this study is linked to our overall strategy of ensuring that patients who are overweight do not get overdosed by dosing on total body weight, or underdosed by giving fixed doses to all patients,” Dr Green said.
“We propose that drugs should be dosed on our formula for lean body weight to match drug exposure across individuals of differing body compositions.
“The results should minimise adverse events and improve efficacy of drugs, which we have already shown in an individualised dosing trial for enoxaparin (a blood thinning drug).”
Source: University of Queensland
Related stories:
Fireflies' glow helps researchers track cancer drug's effectiveness
The gene that allows fireflies to flash is helping researchers track the effectiveness of anti-cancer drugs over time.
Compound has potential for new class of AIDS drugs
Researchers have developed what they believe is the first new mechanism in nearly 20 years for inhibiting a common target used to treat all HIV patients, which could eventually lead to a new class of AIDS drugs.
Novel small molecule therapy shows benefit for anemic patients via hydration of red blood cells
Researchers are identifying innovative therapeutics for sickle cell anemia that focus on specific factors in the disease's progression, such as the important role of hydration of the red blood cells. According to a study prepublished online in
Blood, the official journal of the American Society of Hematology, a novel small molecule therapy called senicapoc showed efficacy in maintaining hydration of red blood cells and increasing hemoglobin levels in patients with sickle cell anemia. Sickle cell anemia affects about 70,000 Americans, and millions worldwide.
Using green chemistry to deliver cutting-edge drugs
Green chemistry is being employed to develop revolutionary drug delivery methods that are more effective and less toxic — and could benefit millions of patients.
Genetic information makes it safer to prescribe common blood thinner
Doctors prescribing blood thinners have had to go through a lengthy trial-and-error process to arrive at the optimal dose for their patients. But now the process can be faster and safer, thanks to research conducted at Washington University School of Medicine in St. Louis.
Genetics determine optimal drug dose of common anticoagulant
Genetic testing can be used to help personalize the therapeutic dosage of warfarin, a commonly-used anticoagulant, according to research published in the September 1, 2007, issue of
Blood, the journal of the American Society of Hematology. This result represents one of the first applications of using an individual’s genetic information to guide personal medical care.
WHO data confirms low level of resistance to Tamiflu
New data published by the World Health Organisation (WHO) has confirmed a low frequency of resistance to Tamiflu (oseltamivir) over 3 influenza seasons (2003 – 2006).
Researchers devise safer way to dose life-saving heart drug
Researchers at the University of Illinois at Chicago have taken the dangerous guesswork out of dosing a lifesaving medication for congestive heart failure.